AUROBINDO

October 12, 2021

| | |
|---|---|
| To<br>Listing Department,<br>**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**<br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br>**MUMBAI -400 051**<br><br>**Company Code No. AUROPHARMA** | To<br>The Corporate Relations Department<br>**BSE LIMITED**<br>Phiroz Jeejeebhoy Towers,<br>25th floor, Dalal Street,<br>**MUMBAI -400 001**<br><br>**Company Code No. 524804** |

Dear Sirs,

**Sub: News item captioned "Aurobindo, MSN to halt Phase 3 trial in moderate Covid patients"**
**Ref : NSE letter No. NSE/CM/Surveillance/11207 dated October 11, 2021.**
**BSE e-mail dated October 11, 2021.**

We refer to your email/letter dated October 11, 2021, seeking clarification on the captioned media report.

Earlier during the year, the Company entered into a non-exclusive voluntary licensing agreement with MSD Pharmaceuticals for their investigational antiviral drug (Covid-19) molnupiravir. The Company has completed the trials for molnupiravir in mild Covid-19 patients as per protocol and the results have come out exceedingly well. The data for the same has been submitted to the Drug Controller General of India (DCGI) already.

The Company has also conducted the trials for molnupiravir in 100 moderate Covid-19 patients. We have faced challenges in patient recruitment at this juncture and are evaluating further course of action.

However, as the matter was not material in nature, the same did not warrant disclosure to the Stock Exchanges, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take note of the above information on record.

Yours faithfully,
**For AUROBINDO PHARMA LIMITED**

**B. Adi Reddy**
**Company Secretary**

AUROBINDO PHARMA LTD. HYDERABAD, INDIA